PDCD1 and non-small cell lung carcinoma: In conclusion, this study paves the way towards the potential predictive role of exosomal immune-oncological proteins and cytokines in monitoring treatment response to anti-PD-1/PD-L1 therapy in NSCLC and identifying subsets of patients who are more likely to benefit from these therapies.